StemSight, a Finnish biotechnology startup developing off-the-shelf regenerative cell therapies for curing blindness, has been granted a patent in Singapore, and received a notice of patent allowance in Canada and Japan, covering the company’s proprietary technology.
The patents strengthen StemSight’s position in the rapidly emerging field of off-the-shelf regenerative medicine and come as the company prepares for its upcoming Series A financing round.
The granted patent family, titled Method for Obtaining or Maintaining ABCG2-Positive Corneal Limbal Cells, protects StemSight’s unique approach in developing STE-101, the company’s novel product for replacing lost limbal stem cells used in the treatment of limbal stem cell deficiency (LSCD), a severe form of corneal blindness for which many patients currently have no effective treatment options.
StemSight’s proprietary technology utilises the generation of functional limbal stem cells from induced pluripotent stem cells (iPS cells), a virtually unlimited starting material, creating the foundation for truly off-the-shelf regenerative therapies that can be manufactured consistently and delivered at scale. This marks a fundamentally different and more practical approach from existing treatment options that require cells derived from adult corneal biopsies.
The company also announced an investment from a new investor, Life Science Invest (LSI Zeta), a Nordic network of business angels in life sciences, further reinforcing confidence in StemSight’s technology platform and long-term commercial potential.
